Monoclonal antibodies (mAbs) are the fastest-growing biological therapeutics with important
applications ranging from cancers, autoimmunity diseases and metabolic disorders to …

Protein aggregation remains a major area of focus in the production of monoclonal
antibodies. Improving the intrinsic properties of antibodies can improve manufacturability …

Aggregation is mediated by local unfolding to allow aggregation “hot spot (s)” to become
solvent exposed and available to associate with a hot spot on another partially unfolded …

Aggregation of mAbs is a crucial concern with respect to their safety and efficacy. Among the
various properties of protein aggregates, it is emerging that their size can potentially impact …

The ability of antibodies to bind to target molecules with high affinity and specificity has led
to their widespread use in diagnostic and therapeutic applications. Nevertheless, a limitation …

Aggregation of a biotherapeutic is of significant concern and judicious process and
formulation development is required to minimize aggregate levels in the final product …

Conjugation of an antibody to a drug can produce heterogeneous species that may have
different physical stabilities and safety profiles. We explored the effect of thermal stress on …

Many human monoclonal antibodies display poor biophysical properties, such as low
stability and a propensity to aggregate. These unfavorable tendencies can be even more …

Antibody–drug conjugates (ADCs) comprised of a desirable monoclonal antibody, an active
cytotoxic drug and an appropriate linker are considered to be an innovative therapeutic …

Monoclonal antibodies (mAbs) have proven to be useful for development of new therapeutic
drugs and diagnostic techniques. To overcome the difficulties posed by their complex …